POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL
40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60, P=.0017) - POLARGO trial results.
DLBCL
Latest Post
No posts found in this category.
